DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

NCT06820255 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Upper Tract Urothelial Cancer

Interventions

DRUG: Platinum + Gemcitabine
DRUG: Avelumab first-line maintenance
DIAGNOSTIC_TEST: NGS test for DDR alterations

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS